Navigation Links
PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
Date:9/21/2012

he age of 18," said Dr. Abraham Havron, CEO of PROLOR.  "hGH-CTP has the potential to dramatically reduce this number, thereby making growth hormone therapy less burdensome and more feasible.  We welcome the opportunity to raise awareness of our progress with hGH-CTP at this meeting of pediatric endocrinology opinion leaders."

Poster P1-d3-296, Once-Weekly, CTP-Modified hGH (MOD-4023) Effectively Maintains IGF-1 Levels Within the Normal Range in Growth Hormone Deficient Adults, Supporting Initiation of Clinical Development in Children, will be presented during the September 22, 2012 poster session of ESPE 2012, which  is being held September 20-23, 2012 in Leipzig, Germany.  For more information, visit http://www.espe2012.org/.

ABOUT PROLOR 
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins.  PROLOR is currently developing a long-acting version of human growth hormone, which successfully completed a Phase II clinical trial.  It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development.  For more information, visit www.prolor-biotech.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, includi
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
2. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
3. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
4. Air Products to Feature Medical and Industrial Grade Gas Solutions for Pharma, Biotech, and Life Science Applications at Mid-Atlantic Bio Conference
5. Biotech Executive Salaries Continue to Rise Despite Weak Economy
6. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
7. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
8. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
9. Germany Prioritizes Medical Biotechnology with New Initiatives
10. Why Texas is #1 in Business: Local BioTech Company Expands
11. RayBiotech, Inc. Achieves Both GMP- and GLP-Compliance and Announces New Dedicated Services Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  The Diabetes Research Institute (DRI), ... Miami Miller School of Medicine, announced today that ... test for the first time a novel transplant ... FDA approved Phase I/II study builds upon decades ... an important first step toward the development of ...
(Date:8/26/2015)... Intrexon Corporation (NYSE: XON ), a ... its previously announced public offering of common stock, including ... option to purchase an additional 731,707 shares of common ... share.  The exercise of the underwriters, option brought the ... Intrexon to 5,609,756 shares and increased the total gross ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... CORAL SPRINGS, Florida , August 26, 2015 ... one of the biggest factors fueling the optimism ... FDA approvals, M&A,s, collaborations and life sciences advancements.  ... and developments are Pressure BioSciences, Inc. (OTCQB: PBIO), ... Inc. (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... to Hold Conference Call Today, March 13, 2008 at 11:00 ... DNDN ) today reported results for the year and ... 31, 2007 were,$743,000 compared to $273,000 for the year ended ... $28,000, compared to $86,000,for the same period in 2006., ...
... VANCOUVER and SAN DIEGO, March 13 /PRNewswire-FirstCall/ - MIGENIX ... for infectious,diseases, reports financial results for the three and ... its programs., Jim DeMesa, M.D., President & CEO ... quarter and now being halfway through our,fourth quarter, we ...
... Patented cathode materials result in longer-lasting, safer batteries for ... ... The U.S. Department of Energy,s,(DOE) Argonne National Laboratory and ... agreement for the commercial production and,sales of Argonne,s patented composite ...
Cached Biology Technology:Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 2Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 3Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 4Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 5MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 2MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 3MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 4MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 5MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 6MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 7MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 8MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 9MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 10MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 11MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 12MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 13MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 14MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 15MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 16Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 2Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 3
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... of the IOF Board and leading researcher at the ... of the prestigious Pierre Delmas Award. The award was ... Osteoarthritis (ESCEO13-IOF), currently being held in Rome, Italy. ... (IOF) in memory of Pierre D. Delmas, IOF,s renowned ...
... between road traffic and heart disease has been suggested in ... Denmark showed that traffic noise was significantly associated with risk ... noise exposure (either at the time of the attack or ... increased risk.(1) Now, a new study presented at the ...
... Albert Einstein College of Medicine of Yeshiva University ... in white blood cells is regulated. HIV-1 is the virus ... approaches for addressing HIV-1 "in hiding" namely eliminating reservoirs ... study was published today in the online edition of the ...
Cached Biology News:Pierre Delmas Award presented in Rome to Professor Socrates Papapoulos 2Long-term exposure to fine particles of traffic pollution increases risk of heart disease 2Discovery may help prevent HIV 'reservoirs' from forming 2
... Features, Special optically clear polystyrene formulation ... in immunoassay applications , Plates are ... coefficients of variation , Eight-well strips ... strip loss while in use even if ...
...
... Pierce scientists developed the Easy-Titer Human IgM ... a simple, sensitive, and easy-to-perform assay for ... an ELISA. This kit incorporates a simple ... of IgM concentration from 15-500 ng/ml in ...
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
Biology Products: